The molecular mechanism and therapeutic strategy of metabolic disorder in renal diseases are the focus of medical research at present. As an important excretory and regulatory organ of human body, the dysfunction of kidney will lead to electrolyte imbalance, acid-base balance disorder, abnormal blood lipid and blood sugar and other metabolic disorders. In this paper, the molecular mechanism of metabolic disorder in renal diseases is reviewed, and the targeted treatment strategies are discussed. Studies have shown that mechanisms such as gene mutation, abnormal signal pathway and inflammatory reaction play an important role in metabolic disorder. Gene editing techniques such as CRISPR-Cas9 provide new possibilities for gene therapy, while targeted therapy and the use of metabolic regulators provide effective means to correct metabolic disorders. In addition, this study also emphasizes the importance of paying attention to and correcting metabolic disorders in the treatment of renal diseases in order to improve the prognosis and quality of life of patients. Future research needs to further explore the molecular mechanism of metabolic disorders and develop more accurate and personalized treatment programs.

Cao Yu. Molecular mechanism and therapeutic strategy of metabolic disorder in renal diseases. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 6: 39-44. https://doi.org/10.25236/IJFM.2024.060606.

[1] Br Er, S., & Palacín, Manuel. (2011). The role of amino acid transporters in inherited and acquired diseases. Biochemical Journal, 436(2), 193-211.

[2] Picaud, S., Kavanagh, K. L., Yue, W. W., Lee, W. H., & Oppermann, U. (2011). Structural basis of fumarate hydratase deficiency. Journal of Inherited Metabolic Disease, 34(3), 671-676.

[3] Ertan, P., Evrengul, H., Ozen, S., & Emre, S. (2012). A patient with cystinosis presenting like bartter syndrome and review of literature. Iranian Journal of Pediatrics, 22(4), 543-546.

[4] Morace, C., Spadaro, A., Cucunato, M., Tortorella, V., & Freni, M. A. (2010). High serum resistin in chronic viral hepatitis is not a marker of metabolic disorder. Hepato-gastroenterology, 57(102-103), 1215-1219.

[5] Shchelochkov, O. A., Manoli, I., Sloan, J. L., Ferry, S., & Venditti, C. P. (2019). Chronic kidney disease in propionic acidemia. Genetics in Medicine, 21(12), 2830-2835.

[6] Liu, S., Gong, Y., Ren, H., Zhang, W., & Chen, N. (2017). The prevalence, subtypes and associated factors of hyperuricemia in lupus nephritis patients at chronic kidney disease stages 1–3. Oncotarget, 8(34), 57099.

[7] Erickson, & Robert, P. (2013). Current controversies in niemann–pick c1 disease: steroids or gangliosides; neurons or neurons and glia. Journal of Applied Genetics, 54(2), 215-224.

[8] Kestenbaum, B., & Belozeroff, V. (2010). Mineral metabolism disturbances in patients with chronic kidney disease. European Journal of Clinical Investigation, 37(8), 607-622.

[9] Melamed, M. L., Buttar, R. S., & Coco, M. (2016). Ckd-mbd in stage 4 and 5 ckd: what we know in 2015. Advances in Chronic Kidney Disease, 23(4), 262.

[10] Wang, L., Xiang, F., Ji, J., Zou, J., & Cao, X. (2020). Indoxyl sulfate and high-density lipoprotein cholesterol in early stages of chronic kidney disease. Renal Failure, 42(1), 1157-1163.

[11] Ng, B. L., & Anpalahan, M. (2011). Management of chronic kidney disease in the elderly. Internal Medicine Journal, 41(11), 761-768.

[12] Pavlovic, D., Katicic, D., Gulin, T., Josipovic, J., & Orlic, L. (2015). Chronic kidney disease mineral bone disorder. Periodicum Biologorum, 117(1), 81-85.

[13] Coritsidis, G. N., Linden, E., & Stern, A. S. (2011). The role of the primary care physician in managing early stages of chronic kidney disease. Postgraduate Medicine, 123(5), 177-185.

[14] Yamamoto, S., Koyama, D., Igarashi, R., Maki, T., & Kuro-O, M. (2020). Serum endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease and various metabolic dysfunctions in aged patients. Internal Medicine, 59(3), 345-355.

[15] Shi, Y., Zhao, Y., Liu, J., Hou, Y., & Zhao, Y. (2014). Educational intervention for metabolic bone disease in patients with chronic kidney disease: a systematic review and meta-analysis. Journal of Renal Nutrition, 24(6), 371-384.

[16] Mathew, S., Davies, M., Lund, R., Saab, G., & Hruska, K. A. (2010). Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease. European Journal of Clinical Investigation, 36(2), 43-50.

[17] Campbell, D., & Weir, M. R. (2015). Defining, treating, and understanding chronic kidney disease—a complex disorder. Journal of Clinical Hypertension, 17(7), 514-527.

[18] Whitehouse, R. W., Ahmad, G., Kirwadi, A., & Howard, J. M. (2022). Imaging of chronic kidney disease-mineral and bone disorder. Radiologic clinics of North America, 60(4), 547-559.

[19] Kurella, M., Chertow, G. M., Luan, J., & Yaffe, K. (2014). Cognitive impairment in chronic kidney disease. Journal of the American Geriatrics Society, 36(2), 116-117.

[20] Megan, & Vaughan. (2019). Conceptualising metabolic disorder in southern africa: biology, history and global health. BioSocieties, 14(1), 123-142.

[21] Karimzadeh, P., Pirzadeh, Z., Ahmadabadi, F., Jafari, N., Jabbehdari, S., & Nemati, H., et al. (2015). Glutaric aciduria type 1: diagnosis and neuroimaging findings of this neurometabolic disorder in an iranian pediatric case series. International Journal of Developmental Disabilities, 61(3), 177-181.

[22] Vlahos, P., Schensul, S. L., Nanayakkara, N., Chandrajith, R., Haider, L., & Anand, S., et al. (2019). Kidney progression project (kipp): protocol for a longitudinal cohort study of progression in chronic kidney disease of unknown etiology in sri lanka. Global public health, 14(2), 214-226.

[23] Hernandez, D., Kalichman, S. C., Katner, H. P., Burnham, K., Kalichman, M. O., & Hill, M. (2018). Psychosocial complications of hiv/aids-metabolic disorder comorbidities among patients in a rural area of southeastern United States. Journal of behavioral medicine, 41(4), 441-449.

[24] Al Kibria, G. M., & Hasan, M. Z. (2022). Income disparities in prevalence and trends of chronic kidney disease among us adults, 2003–18. Journal of Public Health, 30(9), 2181-2189.

[25] P. García-Martínez, Temprado-Albalat, M. D., Ballester-Arnal, R., Gandhi-Morar, K., Castro-Calvo, J., & Collado-Boira, E. (2020). Predictive model of variables associated with health-related quality of life in patients with advanced chronic kidney disease receiving hemodialysis. Quality of Life Research, 29(7), 1817-1827.